Gut microbiome structure and metabolic activity in inflammatory bowel disease

被引:0
|
作者
Eric A. Franzosa
Alexandra Sirota-Madi
Julian Avila-Pacheco
Nadine Fornelos
Henry J. Haiser
Stefan Reinker
Tommi Vatanen
A. Brantley Hall
Himel Mallick
Lauren J. McIver
Jenny S. Sauk
Robin G. Wilson
Betsy W. Stevens
Justin M. Scott
Kerry Pierce
Amy A. Deik
Kevin Bullock
Floris Imhann
Jeffrey A. Porter
Alexandra Zhernakova
Jingyuan Fu
Rinse K. Weersma
Cisca Wijmenga
Clary B. Clish
Hera Vlamakis
Curtis Huttenhower
Ramnik J. Xavier
机构
[1] Broad Institute of MIT and Harvard,Department of Biostatistics
[2] Harvard School of Public Health,Gastrointestinal Unit and Center for the Study of Inflammatory Bowel Disease
[3] Novartis Institute for Biomedical Research Inc.,Department of Immunology, K.G. Jebsen Coeliac Disease Research Centre
[4] Massachusetts General Hospital and Harvard Medical School,Center for Microbiome Informatics and Therapeutics
[5] Department of Gastroenterology and Hepatology,undefined
[6] University of Groningen and University Medical Center Groningen,undefined
[7] Department of Genetics,undefined
[8] University of Groningen and University Medical Center Groningen,undefined
[9] Novartis Institute for Biomedical Research Inc.,undefined
[10] Department of Pediatrics,undefined
[11] University of Groningen and University Medical Center Groningen,undefined
[12] University of Oslo,undefined
[13] Massachusetts Institute of Technology,undefined
来源
Nature Microbiology | 2019年 / 4卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
The inflammatory bowel diseases (IBDs), which include Crohn’s disease (CD) and ulcerative colitis (UC), are multifactorial chronic conditions of the gastrointestinal tract. While IBD has been associated with dramatic changes in the gut microbiota, changes in the gut metabolome—the molecular interface between host and microbiota—are less well understood. To address this gap, we performed untargeted metabolomic and shotgun metagenomic profiling of cross-sectional stool samples from discovery (n = 155) and validation (n = 65) cohorts of CD, UC and non-IBD control patients. Metabolomic and metagenomic profiles were broadly correlated with faecal calprotectin levels (a measure of gut inflammation). Across >8,000 measured metabolite features, we identified chemicals and chemical classes that were differentially abundant in IBD, including enrichments for sphingolipids and bile acids, and depletions for triacylglycerols and tetrapyrroles. While > 50% of differentially abundant metabolite features were uncharacterized, many could be assigned putative roles through metabolomic ‘guilt by association’ (covariation with known metabolites). Differentially abundant species and functions from the metagenomic profiles reflected adaptation to oxidative stress in the IBD gut, and were individually consistent with previous findings. Integrating these data, however, we identified 122 robust associations between differentially abundant species and well-characterized differentially abundant metabolites, indicating possible mechanistic relationships that are perturbed in IBD. Finally, we found that metabolome- and metagenome-based classifiers of IBD status were highly accurate and, like the vast majority of individual trends, generalized well to the independent validation cohort. Our findings thus provide an improved understanding of perturbations of the microbiome–metabolome interface in IBD, including identification of many potential diagnostic and therapeutic targets.
引用
收藏
页码:293 / 305
页数:12
相关论文
共 50 条
  • [11] Dynamics of metatranscription in the inflammatory bowel disease gut microbiome
    Schirmer, Melanie
    Franzosa, Eric A.
    Lloyd-Price, Jason
    McIver, Lauren J.
    Schwager, Randall
    Poon, Tiffany W.
    Ananthakrishnan, Ashwin N.
    Andrews, Elizabeth
    Barron, Gildardo
    Lake, Kathleen
    Prasad, Mahadev
    Sauk, Jenny
    Stevens, Betsy
    Wilson, Robin G.
    Braun, Jonathan
    Denson, Lee A.
    Kugathasan, Subra
    McGovern, Dermot P. B.
    Vlamakis, Hera
    Xavier, Ramnik J.
    Huttenhower, Curtis
    NATURE MICROBIOLOGY, 2018, 3 (03): : 337 - 346
  • [12] Antimicrobial peptides and the gut microbiome in inflammatory bowel disease
    John Gubatan
    Derek R Holman
    Christopher J Puntasecca
    Danielle Polevoi
    Samuel JS Rubin
    Stephan Rogalla
    World Journal of Gastroenterology, 2021, 27 (43) : 7402 - 7422
  • [13] GUT MICROBIOME OF JAPANESE PATIENTS OF INFLAMMATORY BOWEL DISEASE
    Nakajima, Hitoshi
    GASTROENTEROLOGY, 2020, 158 (06) : S1036 - S1036
  • [14] GUT MICROBIOME STRUCTURE AND METABOLIC ACTIVITY IN DIVERTICULITIS
    Ma, Wenjie
    Mehta, Raaj
    Nguyen, Long H.
    Wang, Yiqing
    Bhosle, Amrisha
    Ghazi, Andrew
    Mclver, Lauren
    Song, Mingyang
    Clish, Clary B.
    Strate, Lisa L.
    Huttenhower, Curtis
    Chan, Andrew T.
    GASTROENTEROLOGY, 2023, 164 (06) : S192 - S193
  • [15] ALTERATION OF THE GUT MICROBIOME FOR PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A REVIEW
    Al-Amrah, H.
    Saadah, O., I
    Mosli, M.
    Edris, S.
    Alhindi, R.
    Bahieldin, A.
    APPLIED ECOLOGY AND ENVIRONMENTAL RESEARCH, 2020, 18 (05): : 7379 - 7392
  • [16] Characterisation and therapeutic manipulation of the gut microbiome in inflammatory bowel disease
    Schulberg, J.
    De Cruz, P.
    INTERNAL MEDICINE JOURNAL, 2016, 46 (03) : 266 - 273
  • [17] The role of gut microbiome in inflammatory bowel disease diagnosis and prognosis
    Zheng, Jiaying
    Sun, Qianru
    Zhang, Jingwan
    Ng, Siew C.
    UNITED EUROPEAN GASTROENTEROLOGY JOURNAL, 2022, 10 (10) : 1091 - 1102
  • [18] Gut microbiome-based therapeutics in inflammatory bowel disease
    Hu, Kelly A.
    Gubatan, John
    CLINICAL AND TRANSLATIONAL DISCOVERY, 2023, 3 (02):
  • [19] The Gut Microbiome in Patients with Anxiety, Depression and Inflammatory Bowel Disease
    Anglin, Rebecca
    Libertucci, Josie
    Wolfe, Melanie
    Lee, Christine
    Moayyedi, Paul
    Surette, Michael
    NEUROPSYCHOPHARMACOLOGY, 2014, 39 : S289 - S289
  • [20] Gut microbiome and metabolome: The crucial players in inflammatory bowel disease
    Yu, Jun
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2023, 38 (01) : 5 - 6